Approach

Summary

Licensing status

Publication and contact information

Drug platforms

Production of antibody-toxin fusion immunotoxins in algae

In vitro and mouse studies suggest algae chloroplasts could be used to produce anticancer immunotoxin fusion proteins. Genetically engineered green algae chloroplasts were used to produce an immunotoxin fusion protein that combined a eukaryotic endotoxin and an antibody domain targeting B cell-specific CD22. The algae-produced immunotoxin-induced death of human B cell lymphoma cells but not normal human B or T cells. In a mouse xenograft model of human lymphoma, the algae-produced immunotoxins inhibited tumor progression and increased survival compared with the antibody domain alone. Next steps include designing a new fusion protein for testing in large animal models.
At least six companies have antibodies targeting CD22 in Phase II testing or earlier to treat various cancers.

SciBX 6(2); doi:10.1038/scibx.2013.48
Published online Jan. 17, 2013

Patent application filed; licensed to Sapphire Energy Inc., a biofuels company

Tran, M. et al. Proc. Natl. Acad. Sci. USA; published online
Dec. 10, 2012;
doi:10.1073/pnas.1214638110
Contact: Stephen P. Mayfield, University of California, San Diego, La Jolla, Calif.
e-mail:

smayfield@ucsd.edu